THE NEXT REVOLUTION IN CELL THERAPY

Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) products to find the next immunologic breakthrough in cancer. That’s how we’re leading today, creating tomorrow.

summit-logo-no-date

UNLOCKING THE FOURTH GREAT WAVE IN CANCER TREATMENT

Watch Allogene’s Dr. Zachary Roberts and STAT’s Laura Chang discuss how "off-the-shelf" CAR T products may again change the treatment of cancer.

summit_people

THE NEXT REVOLUTION IN CELL THERAPY

Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) products to find the next immunologic breakthrough in cancer. That’s how we’re leading today, creating tomorrow.

summit-logo-no-date

UNLOCKING THE FOURTH GREAT WAVE IN CANCER TREATMENT

Watch Allogene’s Dr. Zachary Roberts and STAT’s Laura Chang discuss how "off-the-shelf" CAR T products may again change the treatment of cancer.

LEADING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR Tâ„¢ PLATFORM

Innovation

INNOVATION

  • Multiplex gene-engineering and gene-editing capabilities
  • Proprietary lymphodepletion platform
  • State-of-the-art manufacturing
  • Opportunity for product optimization
Pipeline Icon

PIPELINE

  • CD19
    • ALLO-501A – Phase 2
  • BCMA
    • ALLO-715 – Phase 1
    • ALLO-605 – Phase 1
  • CD70
    • ALLO-316 – Phase 1
Leadership

LEADERSHIP

  • A highly experienced management team that includes key pioneers of CAR T cell products
  • Approximately 350 employees singularly focused on the development of AlloCAR Tâ„¢ products
  • Allogene is proud to have approximately 50% of our senior leadership team and entire organization identify as female

WE DON’T JUST SEE THE FUTURE.

WE KNOW HOW TO GET THERE.

Our mission is to create and lead the next revolution in cancer treatment by delivering to patients the first allogeneic CAR T cell (AlloCAR Tâ„¢) products for blood cancers and solid tumors

WHY ALLOGENEIC CELL PRODUCTS HAVE THE POTENTIAL TO LEAD THE REVOLUTION

Assess

ACCESS

  • Potential to treat all
    eligible patients
  • Repeat dosing, if needed
  • No need for complex logistics
Cost

COST

  • Scalable and efficient manufacturing
  • Potential to treat 100+ patients from a single manufacturing run
  • Lower ancillary costs of care
Reliability

SPEED/RELIABILITY

  • Off-the-shelf for on-demand treatment
  • Less product variability, made from healthy T cells

OUR PARTNERS

Cellectis
Notch Therapy
Servier

LATEST NEWS